X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ELDER PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ELDER PHARMA BIOCON LTD/
ELDER PHARMA
 
P/E (TTM) x 80.4 -0.2 - View Chart
P/BV x 7.6 0.1 7,500.4% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 BIOCON LTD   ELDER PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
ELDER PHARMA
Jun-14
BIOCON LTD/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,162380 305.8%   
Low Rs483188 256.6%   
Sales per share (Unadj.) Rs194.6491.2 39.6%  
Earnings per share (Unadj.) Rs34.4-3.2 -1,081.4%  
Cash flow per share (Unadj.) Rs48.314.4 335.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs241.9376.5 64.2%  
Shares outstanding (eoy) m200.0020.54 973.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.20.6 730.9%   
Avg P/E ratio x23.9-89.3 -26.8%  
P/CF ratio (eoy) x17.019.7 86.4%  
Price / Book Value ratio x3.40.8 450.6%  
Dividend payout %2.90-   
Avg Mkt Cap Rs m164,4405,833 2,819.0%   
No. of employees `0009.2NA-   
Total wages/salary Rs m7,4702,179 342.8%   
Avg. sales/employee Rs Th4,213.9NM-  
Avg. wages/employee Rs Th809.0NM-  
Avg. net profit/employee Rs Th745.2NM-  
INCOME DATA
Net Sales Rs m38,91110,089 385.7%  
Other income Rs m1,571257 612.2%   
Total revenues Rs m40,48210,346 391.3%   
Gross profit Rs m9,795-792 -1,236.9%  
Depreciation Rs m2,772361 767.2%   
Interest Rs m2602,756 9.4%   
Profit before tax Rs m8,334-3,653 -228.1%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m1,616125 1,291.3%   
Profit after tax Rs m6,881-65 -10,529.5%  
Gross profit margin %25.2-7.8 -320.7%  
Effective tax rate %19.4-3.4 -566.0%   
Net profit margin %17.7-0.6 -2,730.1%  
BALANCE SHEET DATA
Current assets Rs m40,4779,240 438.1%   
Current liabilities Rs m16,7839,998 167.9%   
Net working cap to sales %60.9-7.5 -810.8%  
Current ratio x2.40.9 261.0%  
Inventory Days Days6046 128.7%  
Debtors Days Days8360 138.2%  
Net fixed assets Rs m45,07310,124 445.2%   
Share capital Rs m1,000206 486.1%   
"Free" reserves Rs m47,3775,582 848.7%   
Net worth Rs m48,3777,734 625.6%   
Long term debt Rs m21,0824,889 431.2%   
Total assets Rs m93,94222,882 410.5%  
Interest coverage x33.1-0.3 -10,161.3%   
Debt to equity ratio x0.40.6 68.9%  
Sales to assets ratio x0.40.4 93.9%   
Return on assets %7.611.8 64.6%  
Return on equity %14.2-0.8 -1,683.2%  
Return on capital %12.622.3 56.5%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m12,988307 4,236.1%   
Fx outflow Rs m7,899125 6,304.1%   
Net fx Rs m5,089181 2,806.9%   
CASH FLOW
From Operations Rs m6,40011,754 54.4%  
From Investments Rs m-4,985-561 889.4%  
From Financial Activity Rs m-1,775-6,762 26.3%  
Net Cashflow Rs m-4734,432 -10.7%  

Share Holding

Indian Promoters % 40.4 39.6 102.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.5 112.0%  
FIIs % 10.7 16.8 63.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 36.1 55.1%  
Shareholders   109,995 16,479 667.5%  
Pledged promoter(s) holding % 0.0 77.6 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 22, 2018 02:07 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS